Tanya B. Dorff, MD, FASCO, shares phase 1 data on ABBV-969, an investigational antibody-drug conjugate being explored for metastatic castration-resistant prostate cancer.
Tanya B. Dorff, MD, FASCO
Advertisement
Articles by Tanya B. Dorff, MD, FASCO
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
The ArteraAI Prostate Test: What It Is and How It Works
2
HHS requests testosterone therapy label updates, citing new safety data
3
Retrospective study suggests differences in OAB therapy persistence among older adults
4
FDA gives nod to feasibility study of NanoKnife IRE for benign prostatic hyperplasia
5